O	0	8	Efficacy
O	9	11	of
O	12	19	topical
B-intervention	20	29	Calendula
I-intervention	30	41	officinalis
O	42	44	on
O	45	55	prevalence
O	56	58	of
B-condition	59	68	radiation
I-condition	68	69	-
I-condition	69	76	induced
I-condition	77	87	dermatitis
O	87	88	:
O	89	90	A
O	91	101	randomised
O	102	112	controlled
O	113	118	trial
O	118	119	.

O	120	121	A
O	122	132	randomised
O	133	143	controlled
O	144	149	trial
O	150	153	was
O	154	164	undertaken
O	165	167	to
O	168	175	compare
O	176	179	the
O	180	188	efficacy
O	189	191	of
O	192	199	topical
O	200	209	Calendula
O	210	221	officinalis
O	222	223	(
O	223	232	Calendula
O	232	233	)
O	234	240	versus
B-control	241	249	standard
I-control	250	252	of
I-control	253	257	care
I-control	258	259	(
I-control	259	268	Sorbolene
O	268	269	:
O	270	272	10
O	272	273	%
O	274	283	glycerine
O	284	286	in
O	287	299	cetomacragol
O	300	305	cream
O	305	306	)
O	307	309	in
O	310	318	reducing
O	319	322	the
O	323	333	prevalence
O	334	336	of
O	337	346	radiation
O	346	347	-
O	347	354	induced
O	355	365	dermatitis
O	366	368	in
B-eligibility	369	374	women
I-eligibility	375	385	undergoing
I-eligibility	386	392	breast
I-eligibility	393	399	cancer
I-eligibility	400	412	radiotherapy
O	412	413	.

O	414	415	A
O	416	421	total
O	422	424	of
B-total-participants	425	428	271
O	429	434	women
O	435	439	were
O	440	448	screened
O	449	452	and
B-total-participants	453	455	82
O	456	460	were
O	461	471	randomised
O	471	472	.

O	473	476	The
O	477	484	primary
O	485	492	outcome
O	493	496	was
B-outcome-Measure	497	507	prevalence
I-outcome-Measure	508	510	of
I-outcome-Measure	511	516	acute
I-outcome-Measure	517	526	radiation
I-outcome-Measure	526	527	-
I-outcome-Measure	527	534	induced
I-outcome-Measure	535	545	dermatitis
I-outcome-Measure	546	547	(
I-outcome-Measure	547	551	RTOG
I-outcome-Measure	552	557	grade
I-outcome-Measure	558	559	2
I-outcome-Measure	559	560	+
I-outcome-Measure	560	561	)
O	562	570	assessed
O	571	573	at
O	574	582	multiple
O	583	587	skin
O	588	593	sites
O	593	594	.

O	595	596	A
O	597	600	chi
O	600	601	-
O	601	608	squared
O	609	613	test
O	614	617	was
O	618	627	conducted
O	628	631	for
O	632	635	the
O	636	643	primary
O	644	651	outcome
O	652	656	with
O	657	658	a
O	659	664	worst
O	664	665	-
O	665	669	case
O	670	678	scenario
O	679	689	imputation
O	689	690	.

O	691	694	The
O	695	706	recruitment
O	707	713	target
O	714	715	(
O	715	716	n
O	717	718	=
O	719	722	178
O	722	723	)
O	724	727	was
O	728	731	not
O	732	740	achieved
O	740	741	.

O	742	743	A
O	744	749	total
O	750	752	of
O	753	754	n
O	755	756	=
B-total-participants	757	759	81
O	760	772	participants
O	773	777	were
O	778	786	analysed
O	787	788	(
O	788	789	n
O	790	791	=
B-intervention-participants	792	794	40
O	795	804	Calendula
O	804	805	;
O	806	807	n
O	808	809	=
B-control-participants	810	812	41
O	813	822	Sorbolene
O	822	823	)
O	823	824	.

O	825	830	There
O	831	834	was
O	835	837	no
O	838	848	detectable
O	849	859	difference
O	860	862	in
O	863	873	prevalence
O	874	876	of
B-outcome	877	886	radiation
I-outcome	886	887	-
I-outcome	887	894	induced
I-outcome	895	905	dermatitis
I-outcome	906	911	grade
I-outcome	912	913	2
I-outcome	913	914	+
O	915	922	between
O	923	926	the
O	927	936	Calendula
O	937	938	(
B-iv-bin-percent	938	940	53
I-iv-bin-percent	940	941	%
O	941	942	)
O	943	946	and
O	947	956	Sorbolene
O	957	958	(
B-cv-bin-percent	958	960	62
I-cv-bin-percent	960	961	%
O	961	962	)
O	963	969	groups
O	970	971	(
O	971	978	primary
O	979	987	analysis
O	988	990	OR
O	991	992	=
O	993	994	0
O	994	995	.
O	995	997	87
O	997	998	,
O	999	1001	95
O	1001	1002	%
O	1003	1005	CI
O	1005	1006	:
O	1007	1008	[
O	1008	1009	0
O	1009	1010	.
O	1010	1012	36
O	1012	1013	,
O	1014	1015	2
O	1015	1016	.
O	1016	1018	09
O	1018	1019	]
O	1019	1020	,
O	1021	1022	P
O	1023	1024	=
O	1025	1026	0
O	1026	1027	.
O	1027	1029	92
O	1029	1030	;
O	1031	1040	covariate
O	1041	1049	adjusted
B-outcome	1050	1058	complete
I-outcome	1059	1063	case
I-outcome	1064	1072	analysis
O	1073	1075	OR
O	1076	1077	0
O	1077	1078	.
O	1078	1080	40
O	1080	1081	,
O	1082	1084	95
O	1084	1085	%
O	1086	1088	CI
O	1088	1089	:
O	1090	1091	[
O	1091	1092	0
O	1092	1093	.
O	1093	1095	13
O	1095	1096	,
O	1097	1098	1
O	1098	1099	.
O	1099	1101	20
O	1101	1102	]
O	1102	1103	,
O	1104	1105	P
O	1106	1107	=
O	1108	1109	0
O	1109	1110	.
O	1110	1112	10
O	1112	1113	)
O	1113	1114	.

O	1115	1119	This
O	1120	1130	randomised
O	1131	1141	controlled
O	1142	1147	trial
O	1148	1154	showed
O	1155	1157	no
O	1158	1168	difference
O	1169	1176	between
O	1177	1186	Calendula
O	1187	1190	and
O	1191	1199	standard
O	1200	1202	of
O	1203	1207	care
O	1208	1209	(
O	1209	1218	Sorbolene
O	1218	1219	)
O	1220	1223	for
O	1224	1227	the
O	1228	1238	prevention
O	1239	1241	of
O	1242	1251	radiation
O	1251	1252	-
O	1252	1259	induced
O	1260	1270	dermatitis
O	1270	1271	.

O	1272	1279	However
O	1279	1280	,
O	1281	1284	the
O	1285	1290	study
O	1291	1294	was
O	1295	1307	underpowered
O	1308	1309	(
O	1309	1316	limited
O	1317	1328	recruitment
O	1328	1329	)
O	1330	1333	for
O	1334	1337	the
O	1338	1345	primary
O	1346	1356	comparison
O	1356	1357	.
